Latest Clinical Trial Milestones News

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.

Resonance Health reports a solid quarter with key clinical trial milestones, expansion of trial sites, and multi-year Software-as-a-Medical Device contracts, underpinning a positive cashflow outlook.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.